Brief: Aravive Announces First Patient Dosed In Phase 2 Study Of Batiraxcept In Clear Cell Renal Cell Carcinoma
31/01/2022 12:07
Jan 31 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF
BATIRAXCEPT IN CLEAR CELL RENAL CELL CARCINOMA
Source text for Eikon: ID:nGNX15v05H
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))